Stemline talks SL-401, ASH; shares rally

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Stemline Therapeutics (STML +11.2%) rallies after saying investigators will give a clinical update of SL-401 in blastic plasmacytoid dendritic cell neoplasm at ASH.

Also on the agenda: Preclinical data for SL-401 in multiple myeloma and chronic eosinophilic leukemia and preclinical data from SL-101 in AML.

The company announces one new BPDCN patient CR and notes that "to date there have been 5 CRs and 1 PR" out of seven evaluable patients for an ORR of 86%. (PR)

Previously: Aegis sees SL-401 peak sales of $800M to $3B.